-
NSCLC (Non Small Cell Lung Cancer)
- Commonly related to smoking or exposures but can see it in non-smokers (adenocarcinoma) with de-novo mutations
- Staging --> PET Scan, CT Chest, MRI Brain given potential to metastasize to CNS
- Stage IV has poor prognosis and median survival of less than 1 year
- Survival is slightly better if you have a driver mutation
Posted 01/25/17 09:20:25 AM by Ying Liu
-
Driver Mutations to Check for in Lung Cancer
- EGFR
- Epidermal growth factor receptors (EGFR) are tyrosine kinases that control growth. Mutations in these receptors that cause them to be constitutively active can lead to cancer
- Mutations in EGFR are seen in 15% of NSCLC adenocarcinoma and are even more frequent in women and non-smokers
- Erlotinib in an EGFR TKI and is associated with improved PFS but not OS compared with chemotherapy
- Resistance to these EGFR TKI’s is common and can lead to progression of disease
- Toxicities include rash, diarrhea and uncommonly interstitial pneumonitis
- ALK
- Anaplastic lymphoma kinase (ALK) rearrangements result in oncogenes that encode a constitutively active kinase
- This rearrangement is seen in 4-7% of NSCLC but may be more common in non-smokers, those with adenocarcinoma and those without an EGFR mutation
- Patients are usually younger
- Crizotinib can be used as initial therapy or can be given following chemotherapy regardless of progression
- Phase III trials showed improved PFS and quality of life but no differences in OS as compared with chemotherapy
- May also have moderate activity against brain metastases
- Generally well tolerated but toxicities include GI sides effects, LFT abnormalities, pneumonitis, cardiac toxicity (bradycardia and QTc prolongation), drug interactions with CYP3A4 inhibitors, and hypersensitivity reactions
Posted 01/25/17 09:24:14 AM by Ying Liu
-
For further reading...
Posted 01/25/17 09:25:06 AM by Ying Liu
Created by Christopher Kelly
Know a hypochondriac? Get them the best-selling book 'AM I DYING?!: A Complete Guide to Your Symptoms, and What to Do Next'
The information on the website does not constitute official guidelines except where explicitly stated.
It is not meant to replace the advice of a health professional.